Apple Must Pay $634 Million in Smartwatch Patent Infringement Case
A federal jury has delivered a verdict that could be the final nail in the coffin for Apple's smartwatch designs, ruling that the tech giant must pay $634 million to medical tech company Masimo. The decision stems from a longstanding legal battle between the two companies over patents related to blood-oxygen tracking technology.
At the heart of the dispute is a patent held by Masimo, which tracks blood-oxygen levels using sensors that can be integrated into wearable devices like smartwatches. Apple's Apple Watch series, including its popular Workout and Heart Rate apps, allegedly infringe on this patent. According to the jury, these features are essentially identical to those described in Masimo's patent.
However, Apple is not backing down, disputing the verdict and arguing that one of the patents in question has already expired. The company claims that the technology in question is "historic" and specific to patient monitoring devices from decades ago, rendering it irrelevant to modern smartwatches.
Despite this disagreement, Masimo appears to have won a significant victory, at least for now. Apple plans to appeal the decision, but for now, the verdict stands. The case has left many wondering whether this ruling will be enough to force Apple to make significant changes to its smartwatch designs or if it will simply lead to more back-and-forth in the courts.
In related news, Masimo and Apple are entangled in a web of separate lawsuits that pre-date this California verdict. In August, Apple rolled out an updated blood-oxygen monitoring feature on select smartwatches after temporarily halting sales of its Series 9 and Ultra 2 models to avoid infringing on Masimo's patents. The redesign was approved by the US Customs and Border Protection, but Masimo has continued to push back, filing a new lawsuit against the agency for allegedly overstepping its authority in allowing the sale of these updated smartwatches without input from Masimo.
As the case continues to play out, one thing is clear: Apple's smartwatch designs are under intense scrutiny, and the tech giant must navigate this complex landscape carefully if it hopes to avoid a costly settlement.
A federal jury has delivered a verdict that could be the final nail in the coffin for Apple's smartwatch designs, ruling that the tech giant must pay $634 million to medical tech company Masimo. The decision stems from a longstanding legal battle between the two companies over patents related to blood-oxygen tracking technology.
At the heart of the dispute is a patent held by Masimo, which tracks blood-oxygen levels using sensors that can be integrated into wearable devices like smartwatches. Apple's Apple Watch series, including its popular Workout and Heart Rate apps, allegedly infringe on this patent. According to the jury, these features are essentially identical to those described in Masimo's patent.
However, Apple is not backing down, disputing the verdict and arguing that one of the patents in question has already expired. The company claims that the technology in question is "historic" and specific to patient monitoring devices from decades ago, rendering it irrelevant to modern smartwatches.
Despite this disagreement, Masimo appears to have won a significant victory, at least for now. Apple plans to appeal the decision, but for now, the verdict stands. The case has left many wondering whether this ruling will be enough to force Apple to make significant changes to its smartwatch designs or if it will simply lead to more back-and-forth in the courts.
In related news, Masimo and Apple are entangled in a web of separate lawsuits that pre-date this California verdict. In August, Apple rolled out an updated blood-oxygen monitoring feature on select smartwatches after temporarily halting sales of its Series 9 and Ultra 2 models to avoid infringing on Masimo's patents. The redesign was approved by the US Customs and Border Protection, but Masimo has continued to push back, filing a new lawsuit against the agency for allegedly overstepping its authority in allowing the sale of these updated smartwatches without input from Masimo.
As the case continues to play out, one thing is clear: Apple's smartwatch designs are under intense scrutiny, and the tech giant must navigate this complex landscape carefully if it hopes to avoid a costly settlement.